101 related articles for article (PubMed ID: 24717108)
1. Recent and current Phase II clinical trials in endometrial cancer: review of the state of art.
Lheureux S; Wilson M; Mackay HJ
Expert Opin Investig Drugs; 2014 Jun; 23(6):773-92. PubMed ID: 24717108
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in endometrial cancer treatment.
Morotti M; Valenzano Menada M; Venturini PL; Ferrero S
Expert Opin Biol Ther; 2012 May; 12(5):649-58. PubMed ID: 22428875
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy for recurrent endometrial cancer: a review of North American trials.
Dellinger TH; Monk BJ
Expert Rev Anticancer Ther; 2009 Jul; 9(7):905-16. PubMed ID: 19589030
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for endometrial cancer.
Amadio G; Masciullo V; Ferrandina MG; Scambia G
Expert Opin Emerg Drugs; 2014 Dec; 19(4):497-509. PubMed ID: 25330855
[TBL] [Abstract][Full Text] [Related]
5. Ixabepilone for the treatment of endometrial cancer.
Marchetti C; Piacenti I; Imperiale L; De Felice F; Boccia S; Di Donato V; Perniola G; Monti M; Palaia I; Muzii L; Benedetti Panici P
Expert Opin Investig Drugs; 2016; 25(5):613-8. PubMed ID: 26949829
[TBL] [Abstract][Full Text] [Related]
6. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details.
Myers AP
Clin Cancer Res; 2013 Oct; 19(19):5264-74. PubMed ID: 24089439
[TBL] [Abstract][Full Text] [Related]
7. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
8. Molecular targets and targeted therapeutics in endometrial cancer.
Weigelt B; Banerjee S
Curr Opin Oncol; 2012 Sep; 24(5):554-63. PubMed ID: 22581357
[TBL] [Abstract][Full Text] [Related]
9. Is there any place for cytotoxic chemotherapy in endometrial cancer?
Steer C; Harper P
Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):447-67. PubMed ID: 11476565
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials.
Hogberg T
Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):463-9. PubMed ID: 18467080
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment.
Wei XW; Zhang ZR; Wei YQ
Expert Opin Investig Drugs; 2013 Sep; 22(9):1181-92. PubMed ID: 23782133
[TBL] [Abstract][Full Text] [Related]
12. Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments.
Lheureux S; Oza AM
Eur J Cancer; 2016 May; 59():99-108. PubMed ID: 27017291
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapeutics for primary peritoneal cancer.
Slomovitz BM; Worley MJ; Markman M; Coleman RL
Expert Opin Emerg Drugs; 2011 Mar; 16(1):71-84. PubMed ID: 21352070
[TBL] [Abstract][Full Text] [Related]
14. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer.
Goodwin RA; Jamal R; Tu D; Walsh W; Dancey J; Oza AM; Elit L; Eisenhauer EA
Gynecol Oncol; 2013 Nov; 131(2):315-20. PubMed ID: 23938374
[TBL] [Abstract][Full Text] [Related]
15. An update on the current pharmacotherapy for endometrial cancer.
de Haydu C; Black JD; Schwab CL; English DP; Santin AD
Expert Opin Pharmacother; 2016; 17(4):489-99. PubMed ID: 26629895
[TBL] [Abstract][Full Text] [Related]
16. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.
Synakiewicz A; Stachowicz-Stencel T; Adamkiewicz-Drozynska E
Expert Opin Investig Drugs; 2014 Nov; 23(11):1517-29. PubMed ID: 24965808
[TBL] [Abstract][Full Text] [Related]
17. Update on the chemotherapeutic management of endometrial cancer.
Bregar A; Robison K; Dizon DS
Clin Adv Hematol Oncol; 2014 Oct; 12(10):659-65. PubMed ID: 25658891
[TBL] [Abstract][Full Text] [Related]
18. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
National Institutes of Health Consensus Development Panel
J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
[TBL] [Abstract][Full Text] [Related]
19. The current state of pemetrexed in ovarian cancer.
Miller RE; Banerjee S
Expert Opin Investig Drugs; 2013 Sep; 22(9):1201-10. PubMed ID: 23899335
[TBL] [Abstract][Full Text] [Related]
20. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
